Administration of Cannabis Causes Alterations in Monoamine Oxidase B and Serotonin Receptor 2c Gene Expressions in Wistar Rats

Administration of Cannabis Causes Alterations in Wistar Rats

  • Oluwatosin Adebisi Dosumu Department of Biochemistry, Federal University of Agriculture, Abeokuta, Nigeria.
  • Oluwafemi Paul Owolabi Department of Biochemistry, Federal University of Agriculture, Abeokuta, Nigeria.
  • Regina Ngozi Ugbaja Department of Biochemistry, Federal University of Agriculture, Abeokuta, Nigeria.
  • Akinola Popoola Department of Crop Protection, Federal University of Agriculture, Abeokuta, Nigeria.
  • Solomon Oladapo Rotimi Department of Biochemistry, Covenant University, Sango Ota, Nigeria.
  • Odunayo Anthonia Taiwo Department of Biochemistry, Chrisland University, Abeokuta, Nigeria
  • Oluwafemi Adeleke Ojo Ojo Landmark University
DOI: https://doi.org/10.5937/afmnai38-28134

Sažetak


This study examined the probable effects of graded doses of Cannabis sativa extract on the gene expressions of Monoamine Oxidase B and serotonin receptor 2C (HTR2C) in an attempt to correlate the duration of use with neurodegeneration tendencies in chronic marijuana users. Male Wistar rats (90 ± 100g) were treated with graded doses of petroleum ether extract of C. sativa (12.5, 25 and 50mg/kg body weight) orally. The exposure was monitored at 4, 8, and 12 weeks for each of the doses employed, after which the brain was removed. The gene expressions were determined by reverse transcriptase polymerase chain reaction. Cannabis considerably (p < 0.05) reduced the relative expression of MAOB at 4 weeks.  At 8 weeks, cannabis upregulated the relative expression of the MAOB gene by 60% Following 12 weeks of exposure to the 50mg/kg body weight dose of C. sativa, 80% increase in the expression of MAOB was observed compared to the control group. C. sativa (50mg/kg body weight) extract at 8 weeks resulted in about 47.7% decrease in the expression of the gene, however, prolonged exposure (12 weeks) to the extract significantly (p < 0.05) increased the relative expression of HTR2C. Cannabis-induced dysregulation of the MAOB genes may be one mechanism linking chronic use of cannabis to cognitive decline and improved likelihood of developing neurological diseases.  Alterations observed in HTR2C gene expression as a result of exposure to high doses of C. sativa extract may partly account for the depression and aggressive tendencies observed in chronic users.

Reference

1. Rosales-Corral S, Hernández L, Gallegos M. Cannabinoids in Neuroinflammation, Oxidative Stress and Neuro Excitotoxicity. Pharmacuetica Analytica Acta 2015; 6:3.
2. Nolen WA, Hoencamp E, Bouvy P.F, Haffmans P.M. "Reversible monoamine oxidase-A inhibitors in resistant major depression". Clinical Neuropharmacology 1993; 16(2): S69–76.
3. Riederer P, Laux G. MAO-inhibitors in Parkinson's disease. Experimental Neurobiology 2011; 20 (1): 1–17.
4. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. "Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography". Neuroscience 1994; 62(1): 15–30.
5. Mallajosyula JK, Chinta SJ, Rajagopalan S, Nicholls DG, Andersen JK. "Metabolic control analysis in a cellular model of elevated MAO-B: relevance to Parkinson's disease". Neurotoxicity Reseach 2009; 16(3): 186–93
6. Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. Journal of Neural Transmisssion Supplementa 2006; 71(71): 53–65.
7. Kumar MJ, Andersen JK.Perspectives on MAO-B in aging and neurological disease: where do we go from here? Molecular Neurobiology 2004; 30(1): 77–89.
8. Dlugos AM, Palmer AA, De Wit H. Negative emotionality: monoamine oxidase B gene variants modulate personality traits in healthy humans. Journal of Neural Transmission 2009; 116(10): 1323–34.
9. Kaludercic N, Carpi A, Nagayama T, Sivakumaran V, Zhu G, Lai EW, et al. Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxidants and Redox Signalling 2014; 20(2): 267–80.
10. López-Ibor JJ. Serotonin and psychiatric disorders. International Clinical Psychopharmacology 1992; 2:5-11.
11. Alenina N, Klempin F. The role of serotonin in adult hippocampal neurogenesis. Behavioural Brain Research 2015; 277:49–57.
12. Stam NJ, Vanderheyden P, Van Alebeek C, Klomp J, De Boer T, Van Delft AM, et al.. Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT2C receptor. European Journal of Pharmacology 1994; 269(3): 339–48.
13. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 2005; 55(4): 242–51.
14. Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott, LH. Serotonin 5-HT (2C) receptors regulate anxiety-like behavior. Genes, Brain and Behavior 2007; 6(5): 491–6.
15. Musty RE, Kaback L. Relationships between motivation and depression in chronic marijuana users. Life Science 1995; 56: 2151–2158.
16. Mark PM, Stuart M, Bronwen M. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Elsevier 2004; 27:10.
17. El-Alfy, Abir T. Antidepressant-like effect of delta-9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacology Biochemistry and Behaviour 2010; 95(4): 434–42.
18. Gruber AJ, Pope HG, Brown ME. Patient’s use of marijuana as an antidepressant. National Institute of Health 1996; 4(2):77-80.
19. Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, et al. RNA editing of the human serotonin 5-HT2C receptor. Alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 2001; 24(5): 478–91.
20. Anja C, Lina E, Rolf S, Elena J. Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis. Biological Psychiatry 2003; 54(11): 1212-1221.
21. Kishore S, Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006; 311(5758): 230–2.
22. Kazuya I, Miki B, Tadafumi K. Serotonin receptor 2C and mental disorders: Genetic, expression, and RNA editing studies. RNA Biology 2009; 6(3):248-253
23. Frank MG, Stryker MP, Tecott LH. Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor. Neuropsychopharmacology 2002; 27:869-73.
24. Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with imagej, Biophotonics Int. 2004; 11:36-42.
Objavljeno
2025/12/21
Broj časopisa
Vol. 38 Br. 1 (2021): Acta facultatis medicae Naissensis
Rubrika
Originalni rad / Original article